Hong Kong · Delayed Price · Currency is HKD Shanghai Junshi Biosciences Company Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.
The company’s product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-α which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer.
It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis.
In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn’s disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn’s disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia.
The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
| Country | China |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,903 |
Contact Details
Address: Building 7 Shanghai, 200126 China | |
| Phone | 86 21 6105 8800 |
| Website | junshipharma.com |
Stock Details
| Ticker Symbol | 1877 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003FF7 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jianjun Zou M.D., Ph.D. | GM, Chief Executive Officer and Executive Director |
| Cong Li | Co-Chief Executive Officer and Executive Director |
| Jun Xiong | Executive Chairman |
| Dr. Ning Li M.D., Ph.D. | Executive Vice-Chairman of the Board |
| Baohong Xu | Chief Financial Officer |
| Zhuobing Zhang | Deputy GM and Executive Director |
| Dr. Sheng Yao Ph.D. | Deputy GM, Senior Vice President and Executive Director |
| Dr. Gang Wang | Chief Quality Officer, Senior Vice President of Industry Affairs and Executive Director |
| Dr. Xin Li | Senior Vice President of Government Affairs and Executive Director |
| Zhengyu Wang | Joint Company Secretary |